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Chapter 8
Part I: Association of biomarkers in resected colorectal liver metastases with 
patient survival
The first aim of this thesis was to identify biomarkers able to help predict patient 
survival after surgery for colorectal liver metastases (CRLM). This is relevant because 
accurate prognostication can guide management for the individual patient, such as the 
administration of adjuvant chemotherapy after liver surgery and a patient-tailored follow-
up (intensity, duration). As high-throughput techniques allow for much wider screening for 
potential biomarkers compared to previous studies, it is important to review the results 
of these high-throughput studies. In addition, although there is growing evidence for the 
importance of immunological processes in cancer behaviour, there have been no recent 
reviews on the topic of CRLM immunology. Therefore, in chapter 2, we reviewed the 
literature on prognostic immunological and molecular markers studied in tumour tissue 
obtained from surgical resection for CRLM. This analysis did not yield a biomarker that 
would be able to predict survival with high accuracy which technically and logistically could 
be easily applied in patient care. However, the quantification of intra-tumoural CD3+ T 
cells and tumoural CXCR4 expression showed the most significant associations with patient 
survival. High infiltration of CD3+ T-cells was associated with a favourable survival and 
high CXCR4 expression with an unfavourable survival. Nevertheless, it was not possible to 
accurately predict patient survival based on tissue-based immunophenotypical markers.
In chapters 3 through 5, we aimed to identify prognostic biomarkers by analysing 
mRNA expression, protein expression, microRNA expression and DNA copy number 
variation. We aimed to improve previous study designs by using more advanced 
experimental methods and stricter patient inclusion criteria. We compared two patient 
groups: poor survivors (who died of recurrences within 30 months after surgery) vs. good 
survivors (those alive without recurrences more than 60 months after surgery).
In chapter 3, we show that high expression of immune-related and stroma-related 
markers in tumour samples was associated with good patient survival. Previously, four 
independent mRNA signatures had been published that aimed to predict patient survival 
after surgery for CRLM [1–4]. However, no single gene was shared between the four 
published signatures, and our own mRNA expression study also showed no overlap with 
the other signatures (chapters 2 and 3). This lack of shared genes might be explained by 
inter-study differences, as these studies used different experimental methods and had 
different patient inclusion criteria and treatment strategies. As discussed in chapter 3, 
previous studies used microarrays while we used mRNA sequencing [1–4]. In addition, 
the rate of administrating chemotherapy differed widely between studies [1,2,4], and this 
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might cause bias because chemotherapy can influence tumour biology and the natural 
course of the disease [5]. To avoid this particular type of (potential) bias, we did not 
include patients treated with neoadjuvant or adjuvant chemotherapy in any of our studies 
(chapters 3-5).
In chapter 3, we demonstrated using immunohistochemistry that high stromal 
infiltration of CD79A+ B cells and Kappa/Lambda+ plasma cells might be associated with 
good survival. This finding questions the role of anti-tumour B-cell immunity. As yet there 
is no consensus: while some authors state that immunoglobulin-production by plasma cells 
and antigen presenting B-cells can enhance anti-tumour immunity, others state that B-cells 
are simply bystanders that are not functional [6,7]. In contrast, B-cell-mediated immune 
suppression, which promotes cancer growth, has also been reported [8]. Additionally, a 
desmoplastic growth pattern, which is characterised by a rim of stromal cells between the 
tumour and the liver parenchyma, might be associated with a good patient survival. Future 
evaluation on larger cohorts is necessary to firmly establish whether these prognostic 
biomarkers can add value to the current clinical models.
In chapter 4, we analysed microRNA expression levels in our cohort and found that 
high expression of miR-196b and miR-19b was associated with poor survival. The number 
of studies on the prognostic role of microRNAs after surgery for CRLM rapidly increased in 
recent years (chapters 2 and 4). All the previous studies used high-throughput methods to 
find prognostic markers, and similar to the mRNA studies, no overlap in prognostic miRNAs 
was observed. Our study showed overlap with one of these studies, but with an effect in 
the opposite direction. We observed an association between poor patient survival and 
high miRNA 196b-5p expression, while Li et al. [9] had observed poor patient survival in 
tumours with low miRNA 196b-5p expression This disagreement between studies might be 
caused by differences in patient inclusion criteria, as Li et al. did not report on neoadjuvant 
chemotherapy or show a multivariable analysis to correct for clinicopathological factors [10].
In chapter 5, we studied copy number variation and showed that a loss of chromosome 
22 was independently associated with a poor patient survival. Although a loss of chr22 is 
not an uncommon feature in oncology, the biological consequence of this phenomenon 
is not well-understood [11,12]. We tried to address a potential biological downstream 
effect of a loss of chr22 by analysing the relation with our mRNA expression data (chapter 
3). Using pathway analysis, we showed that genes related to the immune system are 
associated with a loss of chr22. These findings are comparable to the findings in chapter 
3, which strengthens the hypothesis on the association between patient survival and the 
immune system. Whether there is a causal relation between loss of chr22 and a lower 




Importance of multivariable analysis
In chapters 3 through 5, we performed multivariable analyses to correct for known clinical 
and molecular risk factors to assess the prognostic value of the studied biomarkers. The 
clinical risk score (CRS)[13], which includes five tumour characteristics, is known to be 
associated with patient survival and development of recurrences in large cohorts. In 
addition to these clinical risk factors, we also analysed known molecular risk factors in 
our patient cohorts, namely microsatellite instability status and KRAS/BRAF mutations. 
Previous research has shown that patients with tumours that harbour a BRAF V600E 
mutation have an unfavourable survival compared to BRAF wildtype tumours [14]. Similarly, 
harbouring a KRAS (codon 12 and 13) mutation is associated with an unfavourable survival 
and a lack of response to anti-EGFR treatment [15–20]. However, these molecular risk 
factors were not associated with patient survival in our analyses and did not therefore 
bias the biomarkers we studied (chapters 3-5). One might argue that our cohorts are too 
small to detect a survival advantage for these known molecular markers. However, as we 
aimed to predict survival for the individual patient, we worked to find biomarkers with 
larger effect sizes than currently known biomarkers. In multivariable analyses, we found 
that low stromal infiltration of CD79A+ B cells (chapter 3), low stromal infiltration of K/
L+ plasma cells (chapter 3), a non-desmoplastic growth pattern (chapter 3), high miR-
19b expression (chapter 4) and a loss of chr22 (chapter 5) might be predictors of poor 
patient survival. In addition, clinicopathological factors like a high CRS [13] (chapter 4) and 
male sex (chapters 3 and 4) were also associated with poor patient survival. It has been 
reported that males had a poorer survival [21,22] and more often had early recurrences 
[23] after surgery for CRLM compared to females.
Our total cohort of patients treated in the University Medical Centre Groningen 
(UMCG) consisted of 48 patients, but we were not able to include all 48 tumour samples 
in all experiments. By combining the data from chapters 3-5, we are able to show the 
prognostic value of all studied biomarkers in a subset of 32 patients. For this set of patients, 
we carried out a multivariable analysis including the biomarkers studied in chapter 3 (IHC), 
chapter 4 (microRNA) and chapter 5 (CNV). Table 1 shows that six factors had a p-value 
<0.1 in univariable analysis, and these factors were carried over to the multivariable 
analysis. As miR-19b and miR-17 expression were correlated (r=0.678, p<0.001), we only 
included miR-19b in the multivariable analysis. The multivariable model - which included 
the size of the largest CRLM, desmoplastic growth pattern, miR-19b expression, a loss of 
chr10 and a loss of chr22 - had a Nagelkerke R square of 0.637 and predicted 27 out of 
32 patients (84.4%) in the correct survival group (table 1). In comparison, the five factors 
in the CRS together had a Nagelkerke R square of 0.157 and predicted only 17 out of 30 
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patients (56.7%, 2 missing CEA values) in the correct survival group. The only independent 
prognostic factor in this cohort of 32 patients was a loss of chr22 (p = 0.028, table 1), which 
on its own predicted more patients in the correct survival group than the five CRS factors 
together (23/32 vs. 17/32).
We focussed on tissue-based molecular markers that could add prognostic value to 
the current clinical risk models. But what do we accept as accurate prognostication? As 
biology does not play by statistical rules, prognostic models will probably never reach 
100% accuracy. In statistics, we generally accept a 5% chance that our observation is 
different from the total population. Our multivariable model of 32 patients including only 
5 factors (table 1) placed 84.4% of the patients in the correct survival group, which means 
the model needs to improve by approximately 10% to reach 95% accuracy. Although we 
and others have analysed multiple biological entities to improve prognostication, some 
topics remain unexamined, e.g. genome-wide DNA mutation analysis and long non-coding 
RNA expression. Great promise lies in a multi-omics approach using large cohorts that 
integrates several types of molecular data. The (future) models with the highest prognostic 
value are likely to include genomic, epigenomic, transcriptomic and proteomic data [24,25]. 
In addition, as shown in this thesis, clinicopathological characteristics are a very important 
part of prognostication as well. Molecular and clinical data together might be able to 
predict survival rates and the development of recurrences by exceeding 95% accuracy, 
which would make them of value for the individual patient.
Table 1 Multivariable analysis of the 32 patients in whom all analyses were performed
Univariable Multivariable
P value OR (95% CI) P value
Patient characteristics
Mean age at liver surgery 0.286
Male sex 0.137
Tumour characteristics
Size largest CRLM 0.074 0.751 (0.543-1.038) 0.083
Rectal primary tumour 0.174
Major liver surgery 0.116
Clinical risk score
Interval CRLM < 12 months 0.465
CEA >200 mg/μl 0.417
More than 1 CRLM 0.313
CRLM larger than 5cm 0.530




Table 1 Multivariable analysis of the 32 patients in whom all analyses were performed (continued)
Univariable Multivariable
P value OR (95% CI) P value
Molecular tumour characteristics
Microsatellite instable 0.927
KRAS (codon 12/13) mutation 0.648
BRAF V600E mutation 1.000
Immunophenotypical markers
General lymphocytes
High CD45 tumour stroma 0.893
High CD45 invasive margin 0.514
T-cells
High CD4 tumour stroma 0.466
High CD4 invasive margin 0.946
High CD8 tumour stroma 0.982
High CD8 invasive margin 0.320
High CD8 intra-tumoural 0.648
High FOXP3 tumour stroma 0.172
High FOXP3 invasive margin 0.999
B-cells
High CD79A tumour stroma 0.167
High CD79A invasive margin 0.391
High K/L tumour stroma 0.137
High K/L invasive margin 0.268
High SLAMF7 tumour stroma 0.540
High SLAMF7 invasive margin 0.723
100% desmoplastic growth pattern 0.046 0.059 (0.003-1.094) 0.058
MicroRNA qPCR
High miR-196b expression (> median) 0.154
High miR-19b expression (> median) 0.082 9.099 (0.710-116.669) 0.090
High miR-17 expression (> median) 0.051
Copy number variation
Loss chr10 0.086 3.576 (0.392-32.597) 0.258
Loss chr22 0.018 18.026 (1.366-237.927) 0.028
Percentage of genome changed 0.122
Odds ratio >1 corresponds to poor patient survival. OR = Odds ratio, CI = confidence interval, CRS = clinical 
risk score, CRLM = colorectal liver metastases, CEA = carcinoembryonic antigen, N+ = lymph node positive, 
K/L = Kappa/Lambda.
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Novelty
We identified novel biomarkers that were independently associated with patient survival. 
A high miR-19b expression (chapter 4) and loss of chr22 (chapter 5) were predictive of 
poor survival. Eight other studies analysed prognostication by microRNA expression, and 
none reported a prognostic value for miR-19b expression [10,26–32]. Similarly, we are 
the first group to report an association between loss of chr22 and patient survival [33–
35]. Unfortunately, although many studies present prognostic molecular markers, only a 
few present the same marker as being prognostic (chapters 2-5). This is probably partly 
the result of inter-study differences, e.g. differences in inclusion of patients, treatment 
regimens and experimental methods. Novel prognostic biomarkers therefore need to 
be validated in other cohorts before they can be introduced in clinical care. To improve 
and accelerate this process, collaborations between research groups should be the rule 
rather than the exception. For example, uniform inclusion criteria for patients should be 
agreed upon to establish repeatable results in a second cohort. Alternatively, despite 
proper statistical analyses, previously identified markers (or ours!) may be false positive 
findings and are therefore hard to replicate. Still, it is interesting that multiple studies show 
prognostic value for immune-related markers (chapters 2 and 3).
Future perspectives
We aimed to predict patient survival after surgery for CRLM by measuring the underlying 
tumour biology. The molecular markers we studied might improve prognostication when 
our findings are replicated in other cohorts. Our findings also raise questions about the 
biological function of these markers that have yet to be answered. For example, what is the 
specific function of B cells in tumour immunology (chapter 3)? Which cells are responsible 
for creating a desmoplastic rim around the tumour (chapter 3)? What are the tissue-
specific mRNA targets of miR-19b and miR-196b and how do they influence tumour biology 
(chapter 4)? Does the association between a loss of chr22 and immune-related mRNA 
expression also imply causality (chapter 5)? Future studies may strive to elucidate these 
research questions. However, this does not impair the application of these biomarkers in 
clinical care. These prognostic biomarkers might be incorporated in future guidelines if 
extensive replication in other cohorts shows accurate prognostication.
Accurate prognostication after surgery for CRLM might guide further management 
for the individual patient, e.g. guiding the administration of adjuvant chemotherapy after 
surgery and a patient-tailored follow-up. While adjuvant chemotherapy after liver surgery 
is often a standard treatment in hospitals in the USA, this is not the case in the Netherlands. 




perioperative FOLFOX4 + liver surgery vs. liver surgery alone [36]. In contrast, the study 
did show a marginal benefit in progression-free survival (PFS) for patients receiving 
perioperative chemotherapy, suggesting that a subset of patients might benefit from 
chemotherapy. The question remains whether this marginal PFS benefit can outweigh 
the associated morbidity and costs for large cohorts. Therefore we propose that a more 
personalised approach should be developed in which prognostication might guide adjuvant 
treatment. For example, patients who are highly likely (>95%) to develop a recurrence can 
be administered adjuvant chemotherapy, while patients who are highly likely (>95%) to 
be cured by liver surgery can be spared the chemotherapy.
Part II: The role of thermal ablation in the management of patients with 
colorectal liver metastases
In 75% of all CRLM patients, curation is not possible because of widespread liver 
involvement, extra-hepatic disease or comorbidity [37]. For these patients, only palliative 
chemotherapy or best supportive care can be offered. Radiofrequency ablation (RFA) 
extends the criteria for intentionally curative treatment and therefore increases survival 
rates in the entire population of patients with CRLM [38].
The second aim of this thesis was to study the role of targeted treatment by thermal 
ablation in patients with CRLM, focussing on patient survival. In chapter 6, we concluded 
that RFA, in particular via the percutaneous route, increased the number of patients who 
can be retreated for recurrent CRLM. A repeat intervention was more often possible due to 
treatment with RFA, which can be applied multiple times in a series. Likewise, percutaneous 
RFA was progressively more frequently applied with each additional intervention for 
recurrence of liver metastases. Multivariable analysis showed that, in this large cohort, 
the known clinical factors included in the CRS were independently associated with overall 
survival. In chapter 7, we analysed the impact of RFA in simultaneous surgery for both the 
primary colorectal cancer (CRC) and synchronous CRLM in one surgical session. We found 
that RFA can be applied safely and successfully in adjunct to resection of the primary CRC 
and CRLM. Patients who underwent RFA + partial liver resection had a lower complication 
severity compared to patients who only underwent a partial liver resection. In addition, 
the type of surgery for the primary tumour turned out to be critically associated with 
morbidity. Patients who underwent an abdominoperineal resection more often suffered 
from postoperative complications. Although patients more often developed recurrences 
after treatment with RFA (chapter 6), we did not observe differences in survival rates 
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comparing RFA with partial liver resection (chapters 6 and 7). Therefore we concluded that 
RFA is a very useful addition to the treatment armamentarium in the surgical management 
of CRLM.
Patient selection
There is considerable variation in survival rates among studies that compare RFA with 
partial liver resection, which remains the gold standard treatment for CRLM. In most 
studies, patients undergoing a partial liver resection had more favourable survival 
rates compared to RFA [39–44]. A recent meta-analysis compared RFA + partial liver 
resection vs. partial liver resection alone in 1,918 patients and concluded that there was 
no significant survival advantage for either treatment (HR = 1.24, 95%CI = 0.84-1.84). 
The application of RFA increased the number of patients who were treated with curative 
intent and did not compromise survival rates. They also compared RFA vs. partial liver 
resection in 1,824 patients and showed a survival advantage for patients undergoing a 
partial liver resection (HR = 1.78, 95%CI = 1.35-2.33). Unfortunately, they did not take 
clinicopathological characteristics into account, as the authors of the meta-analysis did 
not have access to this patient data. In our cohort, patients undergoing a partial liver 
resection + RFA had unfavourable clinicopathological characteristics (chapters 6 and 7) 
associated with unfavourable survival rates (data not shown). The selection of suitable 
patients for treatment might therefore already explain the differences in survival rates, 
independent of the treatment chosen.
Biological effect of thermal ablation
Although thermal ablation is included in the Dutch national guidelines as an intentionally 
curative treatment of CRLM [45], the molecular effect of eradicating the tumour by periods 
of heat is not completely understood. The seemingly obvious effect of thermal ablation 
is the physical destruction of tumour cells by hyperthermic injury. However, this process 
is not as obvious as it may seem. The central zone around the tip of the ablation needle 
reaches temperatures above 50° Celsius and quickly undergoes coagulative necrosis. The 
transitional zone reaches temperatures between 41-45° Celsius, which leads to reversible 
damage and cellular apoptosis [46,47]. In response, increased blood flow and chemokines 
are produced, attracting immune cells to the injured site [47]. Tumour antigens that are 
released after tumoural necrosis are taken up by antigen presenting cells, in particular 
dendritic cells, to enhance the immune response [48]. One of the catalysts in the antigen 
presenting process is heat shock protein 70 (HSP70), which can also serve as a cytokine that 




in chapter 6, patients who underwent RFA more often developed recurrences compared 
to patients who underwent surgery. This might be due to incomplete eradication of all 
tumour cells, but one could also speculate that the effect of thermal ablation can be pro-
tumourigenic. Rozenblum et al. showed in two mouse studies that tumour load is higher 
after thermal ablation [50,51]. Their first study described tumour-bearing livers in which 
normal liver parenchyma was ablated, resulting in larger tumours one month after ablation 
compared to sham-operated mice [50]. The second study showed that the proliferative 
markers CDC47 and BrdU were expressed more highly in healthy liver parenchyma after 
RFA, both in the ablated and in the untreated liver lobe [51]. Thus, the accelerated growth 
of tumour cells after RFA might be a hypoxia-driven phenomenon [52]. Future research is 
warranted to study the balance between the anti-tumourigenic immune response and the 
pro-tumourigenic proliferation after thermal ablation. The role of the immune system in 
thermal injury might be used to improve systemic anti-tumour immunity, e.g. by combining 
ablation with immunotherapy [46,47].
Future perspectives
With the good results of observational studies, especially our study in which patients with 
recurrences after previous liver resection can obtain significant survival, it is questionable 
whether a randomisation between resection and ablation is ethical. Anyway, currently 
two randomised trials are running at this moment comparing thermal ablation vs. partial 
liver resection for small resectable CRLM. The COLLISION trial aims to study thermal 
ablation in comparison to partial liver resection in patients with at least one resectable 
and ablatable CRLM and no extrahepatic disease [53]. The primary endpoint is overall 
survival. The aim is to include 687 patients over a timespan of three years at multiple 
hospitals in the Netherlands, and will present their final results after 10 years of follow-
up, which will be around the year 2031 [53]. In addition, the LAVA trial has a similar aim to 
that of the COLLISION trial, but specifically studies patients who are at high surgical risk 
because of their age, comorbidity or tumour load. LAVA aims to include 330 patients and 
will perform follow-up for five years [54]. Of note, there is considerable variation in the 
amount of experience individual centres have with thermal ablation, which might have 
negative influence on the outcome of the patients that underwent ablation. The MAVERRIC 
trial is a prospective multi-institutional study that aims to analyse the strategy of first line 
computer-navigated percutaneous microwave ablation (MWA) vs. partial liver resection 
in tumours ≤ 3cm. This multicenter trial started in 2015 and recruitment is performed 
at the Karolinska Institutet, Sweden, at the University Hospital Bern, Switzerland, and at 
the University Medical Center Groningen, the Netherlands. These centers have extensive 
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experience with ablation of liver tumors and especially with the application of navigation 
guided ablation. The aim is to include a total of 100 participants and compare the 3-year 
survival rate with matched patients who underwent open or laparoscopic resection of liver 
metastases identified in the Swedish liver registry. The results of the MAVERRIC trial are 
expected in 2021 [55]. If MWA proves to be non-inferior to surgery, there will be higher 
level evidence that navigation guided MWA antenna placement is a good alternative to 
surgery.
Additional future perspective: circulating biomarkers
After reviewing the research on prognostication of patients after surgery for CRLM, one 
might speculate about the direction of future studies. Preferably, practitioners should be 
able to have accurate prognostic information shortly after patients are discharged from 
the hospital. In that case, decisions about adjuvant treatment and intensity of follow-up 
can be made without delay. After curative surgery for CRLM, patients are - macroscopically 
- free of tumour, but we know that more than 50% of patients will develop recurrent 
disease [56,57]. The question is in which organ or body fluid the micrometastases, which 
are too small to be detected by currently used CT/MR imaging, are hiding. Next, if we 
know where these tumour cells are hiding, are they able to form new metastases or will 
they eventually undergo apoptosis? Thus, is the detection of micrometastases sufficient 
for accurate prognostication or do these micrometastases also need to harbour certain 
molecular characteristics? In this thesis we analysed surgical tissue specimens for which 
multiple molecular markers were able to predict survival. However, biomarkers detected 
in blood, referred to as liquid biopsies, might be the future. Circulating biomarkers may 
yield information on tumour load and/or the presence of micrometastases that is not 
captured by surgical specimens.
Blood contains several components that can act as a source of biomarkers, e.g. 
circulating tumour cells (CTCs) [58], cell-free tumour DNA [59] and exosomes. Keratin 
20 (CK20) is an epithelial protein used as a biomarker to detect CTCs. Multiple studies 
have reported the number of CTCs as an independent prognostic factor in unresectable 
metastatic CRC, which suggests that it might be a marker of tumour load [60–63]. After 
intentionally curative surgery, however, blood-derived CK20 did not qualify as a reliable 
prognostic biomarker [58,64–66]; it was, instead, bone-marrow-derived CK20 that was 
associated with a poor patient survival [64]. A second study also reported bone-marrow-




marrow aspirations in these two studies were obtained just prior to surgery [64,67]. 
Unfortunately, bone marrow is not as easily accessible as the peripheral blood stream. 
However, if bone marrow is the site in which an accurate biomarker is detectable, it should 
be studied more thoroughly.
Cell-free DNA is mostly released by lymphocytes, but tumours also release their 
DNA by necrosis and apoptosis. The presence of circulating tumour DNA from CRC is 
predominantly identified using PCR-based methods in order to detect driver mutations 
in KRAS and BRAF [59,68,69]. Data on prognostication after surgery for CRLM by cell-free 
DNA is scarce. However, in those patients who had detectable circulating tumour DNA 
a few weeks after surgery for the primary CRC, 58%-94% developed recurrent disease. 
In contrast, only 0%-9.8% of the patients without circulating tumour DNA developed 
recurrences after surgery [69]. In a longitudinal follow-up after surgery or biopsy, tumour 
load can be monitored by quantifying the amount of tumour-specific mutations in a 
personalised PCR assay. This technique might therefore be suitable for prognostication 
and screening in the follow-up [59,68,69].
Exosomes are 40-100 nm vesicles produced by various types of cells, and they act 
like an envelope in which the content is hidden from the outside world [70]. Exosomes 
can contain DNA, mRNAs, microRNAs, proteins, lipids, carbohydrates, metabolites and 
viruses [70–72]. Tumours also secrete exosomes, which are detectable in the bloodstream 
[70,71]. The ‘seed and soil’ theory on the development of metastases described by Paget 
in 1889 suggests that the soil (liver parenchyma) is prepared for the seed (hematogenous 
dissemination of tumour cells) to arrive [73]. Current literature suggests that the content 
of exosomes might have a function in the preparation of the soil [48,74]. For example, 
tumours exposed to hypoxia produced exosomes with improved angiogenic and metastatic 
potential, which suggests that the tumour can adapt to a new situation and effectively 
nest at a new site [75,76]. Prognostication by exosomal content has not been studied in 
CRLM, but results in primary CRC look promising [77–79]. Future research is necessary to 
elucidate which exosomal content might lead to a successful preparation of the soil and 
the formation of new metastases. Circulating biomarkers show great promise and accurate 
predictions are hopefully within reach.
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